Conditions: Growth Hormone Therapy Infant, Small for Gestational Age
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 23
Healthy volunteers: no

Brief summary:
The planned study focuses on the effect of a one year Somatropin treatment (0.035 mg/kg/d or 0.067 mg/kg/d) in short children born SGA on neuromuscular function and cognitive performance.

Detailed description:

Arms:
arm 1: Somatropin for 12 months arm 2: In the first 6 months no intervention, afterwards Somatropin for 12 months

Interventions: intervention 1: Somatropin intervention 2: Somatropin
Intervention descriptions: intervention 1: Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months. intervention 2: Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.

Protocol document: